Viatris Pharmaceuticals
United States 2 duplicate records merged Updated 9 July 2026
Viatris Pharmaceuticals is a finished-dose manufacturer based in United States. It appears in 17 regulatory filings across 1 regulator, without an active US DMF or CEP on file. Its GMP standing is certified by ANVISA (Brazil), EAEU_EEC and MFDS (Korea), among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 13 June 2025 as NAI.
4
registered plants
2 with an FDA FEI number
17
filings
across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.
Inspection history
- 13 June 2025 NAI US FDA
- 17 February 2022 VAI US FDA
- 20 December 2019 VAI US FDA
- 28 March 2018 VAI US FDA
- 26 January 2018 VAI US FDA
- 8 December 2016 NAI US FDA
- 26 July 2016 VAI US FDA
- 2 July 2015 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| BARCELONETA, Puerto Rico | Not on file |
| VENTURA, United States | Not on file |
| Barceloneta, United States | 2627208 |
| Vega Baja, United States | 2623619 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| ARCSA (EC) | 17 | None |
| ANVISA (Brazil) | None | 6 |
| EAEU_EEC | None | 2 |
| MFDS (Korea) | None | 2 |
| US FDA | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Viatris Pharmaceuticals comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was NAI, on 13 June 2025.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates